Interpretation of WHO report 2020-2024: Global tuberculosis report and analysis of key data for China
- VernacularTitle:2020—2024年WHO报告解读：全球结核病报告与中国关键数据分析
- Author:
Ning WANG
1
;
Xixi FENG
2
;
Sheng GONG
1
;
Liangshuang JIANG
1
;
Xiaojun YAO
1
Author Information
1. Public Health Clinical Centre of Chengdu, Chengdu, 610061, P. R. China
2. Department of Public Health, Chengdu Medical College, Chengdu, 610500, P. R. China
- Publication Type:Journal Article
- Keywords:
Tuberculosis;
WHO report;
global trends;
current situation;
prevention and control
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(09):1209-1215
- CountryChina
- Language:Chinese
-
Abstract:
Tuberculosis (TB) remains a major global public health threat. The World Health Organization (WHO) 2020–2024 global TB reports provide a comprehensive overview of the TB situation from 2019 to 2023. In 2023, TB re-emerged as the world's leading infectious killer, with an estimated 10.8 million new cases. While the growth in the incidence rate slowed, the number of deaths decreased to 1.25 million. The COVID-19 pandemic significantly disrupted TB control efforts in 2020–2021. As control measures are gradually restored, a positive trend in TB control is emerging. However, significant regional disparities in incidence persist, with eight high-burden countries, including India and China, accounting for over two-thirds of the global total. In 2023, global treatment coverage for drug-resistant TB (DR-TB) was 44.00% with a treatment success rate of 68.00%; yet, with 400 000 new drug-resistant cases, the control situation remains severe. China has achieved remarkable progress in TB control: new cases fell to 741 000 in 2023 (an incidence of 52 per 100 000); mortality decreased significantly; its share of the global DR-TB burden dropped from 14.00% to 7.30%; and the TB/HIV co-infection rate declined from 1.68% in 2019 to 0.66% in 2023, outperforming the global average. Globally, control measures continue to be optimized: treatment coverage increased from 70.00% in 2019 to 75.00% in 2023, the number of people receiving preventive therapy grew to 4.7 million, and rapid diagnostic coverage reached 48.00%. In China, the number of patients treated recovered to 565 000 in 2023, and rapid diagnostic coverage rose to 74.00%. Although technological innovations have enhanced the efficiency of prevention, screening, diagnosis, treatment, and management, achieving the 2030 End TB Strategy goals will require strengthening TB management, building primary healthcare capacity, and targeting interventions for high-risk populations, while balancing resource allocation with technological innovation to address the challenges of a heterogeneous global epidemic.
